Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Sanders Morris Harris","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Olatec Therapeutics"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Doses First Patient in Phase 2b\/3 Clinical Trial of a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The financing will be used for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout and to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and metabolic diseases.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kaitai Capital

            Deal Size: $83.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing October 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds will be used to advance OLT1177 (dapansutrile) into later stage clinical development. Dapansutrile is an investigational small molecule, that specifically binds to and blocks NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome.

            Lead Product(s): Dapansutrile

            Therapeutic Area: Rheumatology Product Name: OLT1177

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanders Morris Harris

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing February 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY